Observation of the Curative Effect of the Dexamethasone Vitreous Cavity Implant for the Treatment of Irvine-Gass Syndrome.
- Author:
Yu MAO
1
;
Li Qin GAO
1
;
Li Yun JIA
1
;
Si Meng HOU
1
;
Yuan Yuan XIAO
1
;
Xi Wen JI
1
;
Shuang WANG
2
Author Information
- Publication Type:Journal Article
- Keywords: Dexamethasone; Irvine-Gass Syndrome; Macular edema; Vitreous injection
- MeSH: Male; Humans; Female; Middle Aged; Aged; Macular Edema/etiology*; Dexamethasone/therapeutic use*; Intraocular Pressure; Prostheses and Implants; Cataract
- From: Biomedical and Environmental Sciences 2023;36(8):725-731
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To investigate the clinical efficacy of dexamethasone vitreous cavity implants (Ozurdex) for the treatment of macular edema (Irvine-Gass Syndrome) after cataract surgery.
METHOD:Eight patients (eight eyes) with Irvine-Gass syndrome were enrolled for vitreous injections with Ozurdex. The patients included six men (six eyes) and two women (two eyes) with a mean age of 67.12 ± 11.92 years. Changes in the patients best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure were compared before and after treatment.
RESULT:The mean visual acuity BCVA of the patients was 0.81 ± 0.26 before implantation, which improved to 0.20 ± 0.12, 0.13 ± 0.09, and 0.15 ± 0.13 at 2 weeks, 1 month, and 3 months after implantation, respectively ( P < 0.001). The patient's mean CMT before implantation was 703.00 ± 148.88 μm, and it reduced to 258.87 ± 37.40 μm, 236.25 ± 28.74 μm, and 278.00 ± 76.82 μm at 2 weeks, 1 month, and 3 months after implantation, respectively ( P < 0.001).
CONCLUSION:The dexamethasone vitreous cavity implant (Ozurdex) is a safe and effective treatment, which can effectively improve patient's visual acuity and reduce macular edema associated with cataract surgery.